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thrombosis rates to decrease a syndrome, which affects
only 1–8% of the accesses, seems to have an unfavorable
risk benefit profile.
The MILLER measured, standardized banding proce-
dure is successful because it allows for precise application
of resistance into a system.2 This procedure is minimally
invasive and can be performed multiple times just as easily
as it can be undone by simply dilating the band with an
angioplasty balloon. Ligation of the perforating vein
definitely seems to be a good idea in helping the superficial
veins to mature. However, it is unlikely to achieve a high
level of success in the treatment and prevention of DASS.
Although it is a feasible treatment, limited precision of
flow volume reduction and irreversibility lead to the same
problems that made traditional banding procedures
unsuccessful.
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To the Editor: Cotter et al.1 used United States Renal Data
System data from 14,001 incident patients to estimate the
dose–response relationship between epoetin (EPO) and
hematocrit. The authors used their analysis to infer the
maximum effective EPO dose and suggested that this should
inform Federal reimbursement policy. However, the analytic
approach used is inconsistent with FDA guidance and the
inferred maximum dose is not likely to be generalizable to the
US dialysis population. We think it is inadvisable to support
reimbursement policies based on inferential information
without careful consideration of the potential clinical
consequences.
When there is a time delay in clinical response (for
example, hemoglobin) following dosing, FDA recommends
parallel dose–response studies where patients receive constant
doses over fixed time periods with no target ceiling, such as
that proposed by Eschbach et al.2 However, Cotter et al.3 used
observational data containing frequent EPO dose titrations,
analyzed with marginal structural modeling. In studies of
flexible dosing, FDA recommends employing mixed-effects
regression, which accounts for interpatient variability in EPO
responsiveness. This is important because a broad range of
EPO doses (B40-fold) are required to achieve target
hemoglobin levels in individuals.4 The application of
unconventional analytics using observational data should
not supplant knowledge gained by the established approach
of controlled clinical trials designed to estimate dose–re-
sponse. Inferring a maximum effective dose from an
estimated mean might result in inadequate dosing for many
patients. Any new EPO policy should be based on the most
rigorous data and analyses, with careful assessment of the
potential impact.
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Critchlow et al.1 state that ‘the application of unconven-
tional analytics using observational data should not
supplant knowledge gained via the established approach
of controlled clinical trials designed to estimate dose–
response.’ We agree. However, controlled trials might
not provide a generalizable dose–response curve if more
sick patients who require higher doses of erythropoiesis
stimulating agents are under-represented because of
restricted enrollment criteria, patient’s underlying disease
burden, etc. Therefore, controlled trials based on such
restrictions are likely to underestimate the range of
erythropoiesis stimulating agent dose required in the
general hemodialysis population.
In contrast, our analysis of dose–response uses data
from an unselected medicare population and over the dose
range currently used by clinicians. We would encourage
Amgen and others to attempt to resolve the dose–response
issue with appropriately designed clinical trials in a
heterogeneous population. In the absence of such trials,
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carefully designed statistical modeling that appropriately
adjusts for measured time-dependent confounding might
provide answers for policy-makers and others.
1. Critchlow CW, Bradbury BD, Acquavella JF et al. Regarding the effect of
epoetin dose on hematocrit. Kidney Int 2008; 74: 827–828.
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purpura alone or polyangiitis
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To the Editor: We read with interest the article by Zaidi
et al.1 They reported a 17-year-old boy with multiple
vasculitic involvement of the heart, liver, pancreas, kidneys,
and skin, and the authors suggested that these findings might
be secondary to Henoch–Scho¨nlein purpura (HSP). In this
situation, however, we should think about the possibility of
polyangiitis overlap syndrome before concluding that HSP
itself caused multiorgan involvement in this case. As this
overlap has often been diagnosed by postmortem autopsy,
the incidence of polyangiitis overlap syndrome in patients
with HSP is unknown.
Recently, Watanabe et al.2 reported a fatal case of systemic
vasculitis combined with HSP and polyarteritis nodosa in a
56-year-old man. He complained of arthralgia, purpura of
both lower extremities, nasal bleeding, and tarry stool, and
acute renal failure was noted at the time of admission to
hospital. A skin biopsy from the purpura lesion exhibited
leucocytoclastic vasculitis with IgA deposition, and HSP
was considered. However, renal failure progressed rapidly
and subsequently was complicated by acute myocardial
infarction. Postmortem examination revealed polyarteritis
nodosa-type necrotizing vasculitis in the kidneys, heart, and
mesentery resulting in acute multiple infarctions of these
organs, suggesting a polyangitis overlap syndrome.
After reviewing the cases of autopsy, Pacheco et al.3
reported that the reason why systemic necrotizing vasculitis
had been underdiagnosed in the past might partly be due to
the lack of specificity of the most common symptoms and
the paucity of characteristic clinical and organ-specific
manifestations that lead to confusion with more prevalent
conditions.
Therefore, when a patient presents with atypical presenta-
tion of HSP, polyangiitis overlap syndrome should also be
suspected, considering its fatal outcome in contrast to a
benign nature of HSP.
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We thank the authors Dr Jae Shin and Jae Seung Lee1 for
their thoughtful comments. They raise the possibility that
the 17-year-old boy with multiple organ involvement and
IgA deposition on kidney biopsy could have polyangiitis
overlap syndrome (POS). They refer to the report of such
a case by Watanabe et al.2 POS is a term proposed for
cases associated with overlapping features of several forms
of vasculitis, including Henoch-Scho¨nlein purpura (HSP),
Wegener’s granulomatosus, Churg–Strauss syndrome,
microscopic polyangitis (MPA), and polyarteritis nodosa
(PN).2,3 We agree with the authors that the clinical
symptoms in our patient are not very specific to HSP.
POS however, is unlikely for the following reasons. (1) The
renal and skin biopsy findings: Kidney involvement in PN
is characterized by inflammation and fibrinoid necrosis
of renal arteries with sparing of glomeruli. Therefore,
the presence of glomerulonephritis and the absence of
necrotizing arteritis or renal infarction in our patient
argue against PN. (2) In contrast, MPA and HSP are small
vessel vasculitides commonly associated with glomerulo-
nephritis. Pauci-immune necrotizing and crescentic
glomerulonephritis, characterized by glomerular necrosis
without endocapillary hypercellularity on light microscopy
along with the absence or paucity of immune deposits
on immunofluorescence and electron microscopy, is the
typical form of glomerulonephritis in patients with MPA.
In our patient, the presence of endocapillary hyper-
cellularity on light microscopy, strong IgA deposition
in glomeruli and dermal vessels on immunofluorescence,
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